Aridis Pharmaceuticals (NASDAQ:ARDS – Get Free Report) is anticipated to announce its resultson Monday, November 2nd. Analysts expect Aridis Pharmaceuticals to announce earnings of ($0.5960) per share and revenue of $0.27 million for the quarter.
Aridis Pharmaceuticals Price Performance
ARDS opened at $0.00 on Monday. The firm has a market cap of $10,664.20, a P/E ratio of -0.01 and a beta of 47.61. Aridis Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.05.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious infectious diseases. The company’s approach centered on fully human monoclonal antibodies designed to target specific bacterial pathogens and their disease-causing mechanisms, with the goal of providing alternatives or complements to traditional antibiotics.
Aridis’ principal development programs included AR-301, also known as suvratoxumab, an investigational monoclonal antibody directed against Pseudomonas aeruginosa alpha toxin.
Read More
- Five stocks we like better than Aridis Pharmaceuticals
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
